Avelox

Moxifloxacin HCl

Resp tract infections eg, acute exacerbations of chronic bronchitis, community acquired pneumonia (CAP) including CAP caused by multi-drug resistant strains, acute sinusitis; uncomplicated skin & skin structure infections; uncomplicated pelvic inflammatory disease (ie, infections of female upper genital tract, including salpingitis & endometritis); complicated skin & skin structure infections (including diabetic foot infections); complicated intraabdominal infections including polymicrobial infections eg, abscesses.

Adult 400 mg once daily. Duration of treatment for acute exacerbation of chronic bronchitis: 5 days; CAP: 10 days; acute sinusitis: 7 days; uncomplicated skin & skin structure infections: 7 days; uncomplicated pelvic inflammatory disease: 14 days; complicated skin & skin structure infections total treatment duration for sequential therapy (IV followed by oral therapy): 7-21 days; complicated intraabdominal infections total treatment duration for sequential therapy (IV followed by oral therapy): 5-14 days.

May be taken with or without food: Swallow tab whole w/ sufficient liqd.

Hypersensitivity to moxifloxacin or other fluoroquinolones. Pregnancy & lactation.

Discontinue treatment in cases of anaphylactic reactions. Avoid treatment in patients w/ known prolongation of the QT interval & uncorrected hypokalemia; receiving class IA (eg, quinidine, procainamide) or class III (eg, amiodarone, sotalol) antiarrhythmic agents. Patients treated concomitantly w/ drugs that prolong the QT interval eg, cisapride, erythromycin, antipsychotics & TCAs; w/ ongoing proarrhythmic conditions eg, clinically significant bradycardia, acute myocardial ischemia, & liver cirrhosis; in women & elderly who are more susceptible to QTc-prolonging drugs. Fulminant hepatitis, symptoms related to liver failure. Patients w/ known or suspected CNS disorders (eg, lowered convulsion threshold, previous history of convulsion, reduced cerebral blood flow, altered brain structure or stroke), which may predispose to seizures or lower seizure threshold. Antibiotic-associated colitis; patients who develop serious diarrhoea in association w/ use. Myasthenia gravis. Tendinitis & tendon rupture in elderly, during strenuous physical activity, in patients treated concomitantly w/ corticosteroids, in patients w/ renal impairment including renal failure & patients w/ solid organ transplants. Not recommended in patients w/ complicated pelvic inflammatory disease (eg, associated w/ tubo-ovarian or pelvic abscess). Not recommended for the treatment of MRSA infections. May interfere w/ Mycobacterium spp culture test. Peripheral neuropathy. Discontinue use if the patient develops psychiatric reactions. Psychotic patients or patients w/ history of psychiatric disease. Avoid in patients w/ pelvic inflammatory disease, unless fluoroquinolone-resistant N. gonorrhoeae can be excluded. Dysglycemia in elderly diabetic patients receiving concomitant treatment w/ oral hypoglycemic agent (eg, sulfonylurea) or w/ insulin. Careful monitoring of blood glucose in diabetic patients. Aortic aneurysm & dissection particularly in older population. May result in impairment of ability to drive or operate machinery due to CNS reactions & vision disorders. Adolescent & childn.

Mycotic super-infections; headache, dizziness; QT prolongation in patients w/ hypokalaemia; nausea, vomiting, GI & abdominal pains, diarrhea; increase in transaminases; increased γ-glutamyl-transferase.

Impaired absorption leading to lower plasma conc w/ antacids, anti-retroviral drugs (eg, didanosine), minerals, multivit & other prep containing Mg or Al, sucralfate & agents containing Fe or Zn. May increase anticoagulant activity of anticoagulants (warfarin). Reduced systemic availability w/ activated charcoal that prevents further increase of systemic exposure in cases of overdose.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

Rx